Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 2 results out of 2
Data Insights
Omacetaxine mepesuccinate by Teva Pharmaceutical Industries for Relapsed Acute Myeloid Leukemia: Likelihood of Approval
Omacetaxine mepesuccinate is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Relapsed Acute Myeloid Leukemia....
Data Insights
Omacetaxine mepesuccinate by Teva Pharmaceutical Industries for Refractory Acute Myeloid Leukemia: Likelihood of Approval
Omacetaxine mepesuccinate is under clinical development by Teva Pharmaceutical Industries and currently in Phase II for Refractory Acute Myeloid Leukemia....